Immutep (ASX:IMM) will focus on developing its cancer treatment lead candidate eftilagmod alpha in fiscal 2025, Chair Russel Howard said at the annual general meeting, according to a Friday filing with the Australian bourse.

The lead candidate will be evaluated in the phase 3 TACTI-004 trial to investigate its use in patients with first-line non-small cell lung cancer. The trial is set to start later in the year or early next year, the filing said.

The biotechnology firm will also explore the use of eftilagmod alpha to treat head and neck squamous cell carcinoma and metastatic breast cancer, the filing added.

The company's shares were up more than 5% in recent Friday trade.

Price (AUD): $0.30, Change: $+0.02, Percent Change: +5.26%